Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

ABSTRACT Introduction This study investigated the efficacy and safety of teneligliptin as an add‐on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. Materials and Methods In this multicenter, double‐blind, randomized, placebo‐controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0–10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily ( n = 116) or placebo ( n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters. Results At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least‐squares mean difference −0.69%; 95% confidence interval −0.83 to −0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment‐emergent adverse events between the groups. Discussion The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.

Authors

Institutions

Publication Details

Journal
Journal of Diabetes Investigation
Published
2026-11-14
DOI
https://doi.org/10.1111/jdi.70491
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Hye Soon Kim, Jun Sung Moon, Kyong Soo Park, Soo Heon Kwak et al.
Journal of Diabetes Investigation
Diabetes Treatment and Management
article

Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Hye Soon Kim, Jun Sung Moon, Kyong Soo Park, Soo Heon Kwak, Sang Youl Rhee, Jeong Hyun Park, Heung Yong Jin, Chul Woo Ahn, KyungWan Min, Gyuri Kim, Ji A Seo, Sang‐Ah Chang, BokJin Hyun, Jae Hyoung Cho, Sin Gon Kim, Bon Jeong Ku, Hyuk‐Sang Kwon, Sang Yong Kim, Sang Soo Kim, Sung Hee Choi, Kyu Jeung Ahn, Seung Jin Han, Bong‐Soo Cha, SunYoung Kim, Joo Young Nam, Kang Seo Park
article en

Abstract

ABSTRACT Introduction This study investigated the efficacy and safety of teneligliptin as an add‐on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. Materials and Methods In this multicenter, double‐blind, randomized, placebo‐controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0–10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily ( n = 116) or placebo ( n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters. Results At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least‐squares mean difference −0.69%; 95% confidence interval −0.83 to −0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment‐emergent adverse events between the groups. Discussion The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.

Journal of Diabetes Investigation
Inje University (KR), Seoul National University (KR), Chosun University (KR), Yonsei University (KR), Chungnam National University (KR), Korea University (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), Kyung Hee University (KR), Handok (South Korea) (KR), Konkuk University Medical Center (KR), St. Mary's Hospital (US), Chosun University Hospital (KR), The Catholic University of Korea Yeouido St. Mary's Hospital (KR), Inje University Busan Paik Hospital (KR), Pusan National University Hospital (KR), Daejeon Eulji Medical Center, Eulji University (KR), Jeonbuk National University Hospital (KR), National Health Insurance Service Ilsan Hospital (KR), Kyung Hee University Dental Hospital (KR), Chungnam National University Hospital (KR), Gangnam Severance Hospital (KR), St. Mary's Hospital (US), Yeungnam University Medical Center (KR), Kyung Hee University Hospital at Gangdong (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Yonsei University Health System (KR), Korea University (JP), Yeungnam University College (KR), Eulji University Nowon Eulji Medical Center (KR), Korea University Ansan Hospital (KR), Keimyung University (KR), Yeungnam University (KR), Ajou University (KR), Jeonbuk National University (KR), Sungkyunkwan University (KR)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon